• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PER
Click for more information
1.18% 8.4¢

PERCHERON THERAPEUTICS LIMITED

Market Cap $75.73M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a... Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PER
Ann: Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
2 3
01:29 121 27K
01:29 Last post  itsagas Comments Created with Sketch.  121  Views Created with Sketch.  27K 
PER
per-chart
12 13 14
07/06/24 785 191K
07/06/24 Last post  Cuprum29 Comments Created with Sketch.  785  Views Created with Sketch.  191K 
PER
Clean insights and information easily found 		06/06/24 33 8.1K
06/06/24 Last post  bajachris88 Comments Created with Sketch.  33  Views Created with Sketch.  8.1K 
PER
Ann: Phase IIb study of ATL1102 in DMD completes recruitment
2
03/06/24 102 24K
03/06/24 Last post  Brett ebony Comments Created with Sketch.  102  Views Created with Sketch.  24K 
PER
Ann: Percheron to present at 2024 BIO International Convention 		31/05/24 23 5.3K
31/05/24 Last post  Brett ebony Comments Created with Sketch.  23  Views Created with Sketch.  5.3K 
PER
PER - Megathread
4 5 6
30/05/24 326 101K
30/05/24 Last post  itsagas Comments Created with Sketch.  326  Views Created with Sketch.  101K 
PER
Ann: Preliminary Results of 9 Month Toxicology Study of ATL1102 		27/05/24 37 8.2K
27/05/24 Last post  itsagas Comments Created with Sketch.  37  Views Created with Sketch.  8.2K 
PER
Ann: US Patent Granted for ATL1102 in Duchenne muscular dystrophy 		20/05/24 7 2.5K
20/05/24 Last post  itsagas Comments Created with Sketch.  7  Views Created with Sketch.  2.5K 

See All Discussions arrow Created with Sketch.

Timeline

Percheron appoints Dr Cathryn Clary as Chief Medical Advisor
03 Jun 08:31
 
Percheron to present at 2024 BIO International Convention
31 May 08:32
 
Phase IIb study of ATL1102 in DMD completes recruitment
29 May 09:01
 
Preliminary Results of 9 Month Toxicology Study of ATL1102
27 May 09:41
 
US Patent Granted for ATL1102 in Duchenne muscular dystrophy
20 May 08:41
 
WHO selects proposed INN for ATL1102
06 May 08:52
 
View More arrow Created with Sketch.

Featured News

TVN Tivan teams up with Japan's Sumitomo in WA in 'strategic alliance'
right-arrow Created with Sketch.
TLX Telix kicks off $300M NASDAQ IPO offer, backed by Morgan Stanley
right-arrow Created with Sketch.
AZY Drilling doubles gold-copper mineralisation zone at GEO-01 for Antipa
right-arrow Created with Sketch.
NEWS Corporate profits miss buoys ASX200 & why are iron ore and brent crude so low?
right-arrow Created with Sketch.
BB1 BlinkLab jumps as Dutch dementia study kicks off
right-arrow Created with Sketch.
BB1 BlinkLab teams up with Bates College in Maine, USA to re-jig software for FND diagnosis
right-arrow Created with Sketch.
(20min delay)
Last
8.4¢ 		Change
-0.001(1.18%) 		Mkt cap ! $75.73M
Open High Low Value Volume
8.9¢ 8.9¢ 8.2¢ $63.67K 761.2K

Buyers (Bids)

No. Vol. Price($)
1 43210 8.3¢
 

Sellers (Offers)

Price($) Vol. No.
8.7¢ 200 1
View Market Depth
Last trade - 15.59pm 07/06/2024 (20 minute delay) ?
Last
8.4¢ 		  Change
-0.001 ( 3.45 %)
Open High Low Volume
8.9¢ 8.9¢ 8.2¢ 115933
Last updated 14.43pm 07/06/2024 ?
PER (ASX) Chart

Top Stories

Aussie man returns home to take the wheel at Peter Warren

Peter Warren Automotive Holdings (ASX: PWR) has appointed Mr Andrew Doyle as the new chief executive officer of the car sales company.
Walkabout rolls out first graphite shipment from Tanzania's Lindi Jumbo mine Walkabout Resources Ltd has shipped its first on-spec graphite concentrate from the Lindi Jumbo mine in Tanzania.
Morella sharpens the drill bit for lithium targets at Tabba Tabba Morella (ASX: 1MC has commenced drilling at the company’s Tabba Tabba East Project in the Pilbara, Western Australia.
Augustus hits copper and molybdenum sweet spot at Minnie Springs Augustus Minerals Ltd has identified the potential for high grade zones of copper and molybdenum at depth at the Minnie Springs project in WA.
York Harbour signs option agreement with Firetail Resources Firetail Resources has been given an option by York Harbour to acquire an 80% interest in its York Harbour Project in Newfoundland, Canada.

Featured News

LPM Lithium Plus inks spodumene offtake MOU with China's Canmax
right-arrow Created with Sketch.
BB1 BlinkLab jumps as Dutch dementia study kicks off
right-arrow Created with Sketch.
JBY James Bay Minerals jumps 12% as it kicks off exploration run at Joule, Canada
right-arrow Created with Sketch.
CCO Calmer Co taps investors for $2M
right-arrow Created with Sketch.
NEWS Corporate profits miss buoys ASX200 & why are iron ore and brent crude so low?
right-arrow Created with Sketch.
SRG Multiple contract awards puts the wind in SRG's sales
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.